Abstract: Modified release oil in water emulsions that delivers drugs to a target tissue. The emulsions according to the present invention contain the lipophilic active ingredient completely dissolved into the hydrophobic internal phase stabilised by a polymeric surfactant. The presence of this polymer around the hydrophobic droplets avoids the migration of the active ingredient into the external hydrophilic phase and, consequently, its re-crystallization.

Abstract: The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, which form a film after application onto the scalp and/or the hair, which compositions are useful for delivery of actives onto the scalp surface and/or onto the hair.

Abstract: A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. According to a preferred embodiment, the matrix is used in amounts of about 5-60% and the active principle in amounts of about 2-70%, with respect to the weight of the formulation.

Abstract: Method for prevention and treatment of vaginal fungal infections by administering a formulation comprising ascorbic acid or a physiologically acceptable salt thereof to a patient in need of such prevention or treatment. The formulation is administered after completion of the standard treatment against bacterial, fungal or protozoarian infections.

Abstract: The present invention is directed to compositions containing a combination of a herb from the genus Equisetum together with one film forming agent and its use as a nail topical formulation, like nail varnish, cream, gel, lotion or foam. The present invention is further directed to the use of a water soluble film forming agent as an additive in a nail topical formulation. These compositions can be used to treat specific alterations of the ungual structure, with onychoschizia which is a specific alteration of the ungual structure, characterized by lamellar splitting of the nail plate.

Abstract: A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.

Abstract: The present invention is directed to the use of chitosan, a chitosan derivative or a physiologically acceptable salt thereof, to increase nail growth rate. The invention is further directed to the use of chitosans to accelerate nail growth rate during treatment of nail illnesses, nail dystrophy or other nail conditions, in order to shorten considerably the specific treatments of said nail illnesses, nail dystrophy or other nail conditions.

Abstract: Chitosan-based nail formulations are useful to treat nail inflammatory diseases like psoriasis, atopic dermatitis and lichen planus. The chitosan is normally in the form of an amino-polysaccharide derivative, preferably water soluble, such as hydroxypropyl chitosan. The formulation may be a nail lacquer, a spray, a cream, an ointment, a gel, a lotion or a foam and may have a content in chitosan, chitosan derivative or a salt thereof from 0.1 to 25 wt. % with respect to the total weight of the formulation.

Abstract: The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, forming a dermal film after application onto the skin, useful for delivery of actives onto the skin surface and in the stratum corneum.

Abstract: The present invention is directed to compositions containing ascorbic acid or a physiologically acceptable salt thereof for the preparation of a formulation useful for the prevention of fungal infection recurrences or fungal superinfections in patients at risk.

Abstract: The present invention is directed to compositions containing a combination of a herb from the genus Equisetum together with one film forming agent and its use as a nail topical formulation, like nail varnish, cream, gel, lotion or foam. The present invention is further directed to the use of a water soluble film forming agent as an additive in a nail topical formulation. These compositions can be used to treat specific alterations of the ungula structure, like reduced strength, onychoschizia and ungula brittleness.

Abstract: The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchitosans and its use as a nail varnish. The present invention is further directed to the use of a water soluble film forming agent selected from hydroxyalkylchitosans and carboxyalkylchitosans as an additive in a nail varnish.

Abstract: A pharmaceutical formulation for the oral administration of cyclosporin is described, which formulation is capable of providing substantially constant and foreseeable plasma levels of the active ingredient. The formulation has the following quali-quantitative composition by weight: (a) cyclosporin in the amount of from about 8 to about 12% of the total weight; (b) ethanol in the amount of from about 12 to about 18% of the total weight; (c) a polyoxyethylene/polyoxypropylene block copolymer in the amount of from about 8 to about 12% of the total weight; (d) water in the amount of from about 4 to about 6% of the total weight; (e) a solubilizer having an HLB from 13 to 15 in the amount of from about 28 to about 40% of the total weight; (f) an ester of a C1-C6 alkyl alcohol and a C14-C18 saturated fatty acid in the amount of from about 20 to about 30% of the total weight.

Abstract: A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.

Abstract: A pharmaceutical formulation for the oral administration of cyclosporin is described, which formulation is capable of providing substantially constant and foreseeable plasma levels of the active ingredient.

Abstract: The present invention relates to a composition comprising a) at least one antimycotic agent and b) at least one film forming agent wherein component b) is a derivative of chitosan selected from hydroxyalkylchitosans and carboxyalkylchitosans and its use as a nail varnish. The present invention is further directed to the use of a water soluble film forming agent selected from hydroxyalkylchitosans and carboxyalkylchitosans as an additive in a nail varnish.

Abstract: A method of improving bioavailability of ergot derivatives administered using sustained-release delivery systems includes combining an ergot derivative or mixture thereof with a pharmaceutically acceptable hydrophilic swelling agent or mixture thereof and one or more pharmaceutically acceptable excipients. The bioavailability of sustained-release formulations of the present invention is at least equal to the bioavailability of the ergot derivative or mixture thereof administered using a conventional delivery system. Sustained-release compositions that improve bioavailability are also provided. Methods and compositions according to the present invention may provide sustained-release characteristics while improving the bioavailability of ergot derivatives.

Abstract: Bioadhesive microemulsions or liposomic dispersions containing proteinaceous substances, especially calcitonin, that allow the systemic, local or topical administration of drugs by transmucosal route are described. This type of administration shows some considerable advantages of activity, tolerability, dosage individualization and drug stability.

Abstract: Liquid bioadhesive microemulsions or liposomic dispersions containing proteinic substances, especially calcitonin, that allow the systemic, local or topical administration of drugs by transmucosal route are described. This type of administration shows some considerable advantages of activity, tolerability, dosage individualization and drug stability. The compositions contain proteinic substances, and a polyoxyethylene-polyoxypropylene thermosetting copolymer. At body temperature the viscosity of the compositions is increased and provides increase residence time at the administration site.